tetano
Editor, Senior Moderator
Mol Pharm. 2020 May 7. doi: 10.1021/acs.molpharmaceut.0c00371. [Epub ahead of print]
Emerging Biomolecular Testing to Assess Risk of Mortality from COVID-19 Infection.
Mahmoudi M.
Abstract
Severe acute respiratory syndrome coronavirus 2 (a.k.a. SARS-CoV-2 and COVID-19) has produced an unprecedented global pandemic. Though the death rate from COVID-19 infection is ~2%, many infected people recover at home. Among patients for whom COVID-19 is deadly are those with pre-existing co-morbidities. Therefore, identification of populations at highest risk of COVID-19 mortality could significantly improve the capacity of healthcare providers to take early action and minimize the possibility of overwhelming care centers, which in turn would save many lives. Although several approaches have been used/developed (or are being developed/suggested) to diagnose COVID-19 infection, no approach is available/proposed for fast diagnosis of COVID-19 infections likely to be fatal. The central aim of this short perspective is to suggest a few possible nano-based technologies (i.e., protein corona sensor array and magnetic levitation) that could discriminate COVID19-infected people while still in the early stages of infection who are at high risk of death. Such discrimination technologies would not only be useful in protecting health care centers from becoming overwhelmed, but would also provide a powerful tool to better control possible future pandemics with less social and economic burden.
PMID:32379456DOI:10.1021/acs.molpharmaceut.0c00371
Emerging Biomolecular Testing to Assess Risk of Mortality from COVID-19 Infection.
Mahmoudi M.
Abstract
Severe acute respiratory syndrome coronavirus 2 (a.k.a. SARS-CoV-2 and COVID-19) has produced an unprecedented global pandemic. Though the death rate from COVID-19 infection is ~2%, many infected people recover at home. Among patients for whom COVID-19 is deadly are those with pre-existing co-morbidities. Therefore, identification of populations at highest risk of COVID-19 mortality could significantly improve the capacity of healthcare providers to take early action and minimize the possibility of overwhelming care centers, which in turn would save many lives. Although several approaches have been used/developed (or are being developed/suggested) to diagnose COVID-19 infection, no approach is available/proposed for fast diagnosis of COVID-19 infections likely to be fatal. The central aim of this short perspective is to suggest a few possible nano-based technologies (i.e., protein corona sensor array and magnetic levitation) that could discriminate COVID19-infected people while still in the early stages of infection who are at high risk of death. Such discrimination technologies would not only be useful in protecting health care centers from becoming overwhelmed, but would also provide a powerful tool to better control possible future pandemics with less social and economic burden.
PMID:32379456DOI:10.1021/acs.molpharmaceut.0c00371